On September 1, 2022, a new unified program for the treatment of spinal muscular atrophy (SMA) will enter into force. This program includes three treatment options: the previously used drug Spinraza and the newly introduced drugs: Zolgensma (gene therapy) and Evrysdi (oral therapy).
Since April 2021, SMA has been included in the Newborn S...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
